Brief: Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
02/12/2024 13:30
Dec 2 (Reuters) - Spyre Therapeutics Inc SYRE.O :
* SPYRE THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN
PHASE 1
TRIALS OF NOVEL HALF-LIFE EXTENDED ANTI-TL1A ANTIBODIES
* SPYRE THERAPEUTICS INC - INTERIM DATA FOR SPY002 MOLECULES
EXPECTED IN Q2 2025
Source text: ID:nPn8XsB6ta
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock